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Colorectal cancer (CRC) is the third most common cancer among women and men 
in the USA. The KRAS gene is mutated in 40% of the CRC cases and hence the 
RAS pathway activation has become a major focus of drug targeting efforts. 
However, nearly 60% of patients with wild-type KRAS fail to respond to RAS-
targeted therapies, for example the anti-epithelial growth factor receptor inhibitor 
(EGFRi) combination therapies. Thus, there is a need to develop more reliable 
molecular signatures to better predict mutation status. In this study, we develop a 
hybrid (DNA mutation and RNA expression) signature and assess its predictive 
properties for the mutation status of CRC patients. Publicly-available microarray 
and RNA-Seq data from 54 matched formalin-fixed paraffin embedded (FFPE) 
samples from the Affymetrix GeneChip and RNA-Seq platforms, were used to 
obtain differentially expressed genes between mutant and wild-type samples. For 
classification, the support-vector machines, artificial neural networks, random 
forests, k-nearest neighbors and the nave Bayes algorithms were employed. 
Compared to the genelist from each of the platforms, the hybrid genelist had the 
highest accuracy, sensitivity, specificity and AUC for mutation status and could 
therefore be useful in clinical practice, especially for colorectal cancer diagnosis 
and therapeutics. 
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